自体CIK细胞治疗对恶性肿瘤患者免疫功能和生活质量的影响

Effects of autologous CIK cells immunotherapy on the immune function and quality of life of cancer patients

目的:探讨自体细胞因子诱导的杀伤(cytokine-induced killer,CIK)细胞对恶性肿瘤患者免疫功能和生活质量的影响。方法:回顾性分析在我院经过CIK细胞治疗的58例恶性肿瘤患者临床资料,流式细胞仪检测患者治疗前后外周血CD3+、CD3+CD4+、CD3+CD8+、CD3-CD16+CD 56+和CD3+CD16+CD 56+细胞的表达水平;42例患者治疗前后采用世界卫生组织生活质量测定简表(WHOQOL-BREF)分别进行问卷调查;治疗过程中监测相关的不良反应。结果:患者CIK细胞培养液体取样标本中CD3+总T淋巴细胞、CD3+CD4+T辅助淋巴细胞以及CD3+CD8+T抑制淋巴细胞的亚群水平分别为(82.79±11.98)%、(30.32±11.23)%和(49.10±11.65)%,CD4+/CD8+的比值为0.67±0.34,而CD3-CD16+CD56+NK细胞和CD3+CD16+CD56+CIK细胞亚群水平分别为(16.58±11.83)%和(13.74±8.66)%。与治疗前相比,治疗后的患者外周血中CD3+总T淋巴细胞亚群、CD3+CD4+T辅助淋巴细胞亚群、CD3+CD8+T抑制淋巴细胞亚群和CD3+CD16+CD 56+CIK细胞亚群水平均明显升高(P<0.05),CD3-CD16+CD 56+NK细胞亚群水平较治疗前下降(P<0.05)。经过CIK细胞治疗后,患者的生理、心理、社会关系和环境关系均得到很好的改善(P<0.05)。自体CIK细胞治疗过程中不良反应发生率低,均可控制。结论:自体CIK细胞治疗增强了患者的免疫功能,改善了患者的生活质量,且不良反应较轻。

Objective: The aim of the present study is to evaluate the effects of autologous cytokine-induced killer cells( CIK) immunotherapy on immune function and quality of life of cancer patients. Methods: We performed a retrospective analysis of 58 cancer patients who received CIK immunotherapy in our hospital. The T lymphocyte in their peripheral blood samples drew before and after the treatment were analyzed by flow cytometry for CD3+,CD3+CD4+,CD3+CD8+,CD3-CD16+CD56+and CD3+CD16+CD56+subpopulations. Patients were assessed with the WHO QOL-BREF questionnaires to evaluate their quality of life. Treatment-related adverse reactions during treatment were also surveyed. Results: In the culture for generating CIK,the levels of CD3+T lymphocytes,CD3+CD4+T helper cells,CD3+CD8+cytotoxic T cells were( 82. 79 ± 11. 98) %,( 30. 32 ± 11. 23) %,and( 49. 10 ± 11. 65) % respectively. The ratio of CD4+and CD8+T cells was 0. 67 ± 0. 34. Notably,the levels of CD3+CD16+CD56+CIK cells and CD3-CD16+CD56+NK cells were( 16. 58 ± 11. 83) % and( 13. 74 ± 8. 66) %. Comparing the two peripheral blood samples from each patient,the percentages of CD3+T lymphocytes,CD3+CD4+T helper cells,CD3+CD8+cytotoxic T cells,and CD3+CD16+CD56+CIK subsets were all significantly increased after the treatment( P < 0. 05),whereas the percentage of CD3-CD16+CD56+NK cell percentage decreased significantly( P < 0. 05). The QOL-BREF of patients were also improved significantly( P <0. 05),and the treatment-related adverse reactions were well-tolerated in most patients. Conclusion: CIK therapy is safe and effective in improving quality of life and immune functions of patients with malignant tumors.